

60 ~~sec'd~~ PCT/PTO 21 SEP 2001  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**MARCIREAU ET AL.**

Examiner: UNASSIGNED

Serial No.: **09/744,125**

Art Unit: UNASSIGNED

Filed: JANUARY 19, 2001

Title: **MEKK1-INTERACTING FHA  
PROTEIN (M1F1)**

5060

*Handwritten signature/initials*

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents  
Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed copy of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the enclosed copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Sequence Listing can be found in the instant Application as filed.

Respectfully submitted,

*William C. Coppola*  
\_\_\_\_\_  
William C. Coppola, Reg. No. 41,686  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4854  
Telefax (908) 231-2626  
Docket No. A3233A US